BIOMAT Database Logo BIOMAT Database Logo

Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. 2011

Xiao-Dong Ma, and Xuan Zhang, and Hui-Fang Dai, and Shi-Qiong Yang, and Liu-Meng Yang, and Shuang-Xi Gu, and Yong-Tang Zheng, and Qiu-Qin He, and Fen-Er Chen
Department of Chemistry, Fudan University, Shanghai 200433, PR China.

A novel series of benzophenone derivatives with B-ring substituted by naphthyl ring has been synthesized and evaluated as non-nucleoside HIV-1 reverse transcriptase inhibitors. Most of these compounds showed good to moderate activity against wild-type HIV-1 and mutated viruses. In particular, the analogue 10i demonstrated the most potent activity against wild-type HIV-1 with an EC₅₀ value of 4.8 nM, and with a high selectivity index up to 10347.9, it also proved to be active against the HIV-1 double mutant strain A₁₇ (K103N+Y181C) with an EC₅₀ value of 2.1 μM. In addition, the molecular modeling study was used to explore the major interactions between the potent inhibitors with the HIV-1 RT. The investigation of the structure-activity relationships may serve as an important lead for the further optimization.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001577 Benzophenones Derivatives of benzophenone (with the structural formula phenyl-(C
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Xiao-Dong Ma, and Xuan Zhang, and Hui-Fang Dai, and Shi-Qiong Yang, and Liu-Meng Yang, and Shuang-Xi Gu, and Yong-Tang Zheng, and Qiu-Qin He, and Fen-Er Chen
Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
May 2012, European journal of medicinal chemistry,
Xiao-Dong Ma, and Xuan Zhang, and Hui-Fang Dai, and Shi-Qiong Yang, and Liu-Meng Yang, and Shuang-Xi Gu, and Yong-Tang Zheng, and Qiu-Qin He, and Fen-Er Chen
Design, synthesis, and SAR of naphthyl-substituted Diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
September 2009, ChemMedChem,
Xiao-Dong Ma, and Xuan Zhang, and Hui-Fang Dai, and Shi-Qiong Yang, and Liu-Meng Yang, and Shuang-Xi Gu, and Yong-Tang Zheng, and Qiu-Qin He, and Fen-Er Chen
Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors.
July 2010, Bioorganic & medicinal chemistry,
Xiao-Dong Ma, and Xuan Zhang, and Hui-Fang Dai, and Shi-Qiong Yang, and Liu-Meng Yang, and Shuang-Xi Gu, and Yong-Tang Zheng, and Qiu-Qin He, and Fen-Er Chen
Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
August 2006, Bioorganic & medicinal chemistry letters,
Xiao-Dong Ma, and Xuan Zhang, and Hui-Fang Dai, and Shi-Qiong Yang, and Liu-Meng Yang, and Shuang-Xi Gu, and Yong-Tang Zheng, and Qiu-Qin He, and Fen-Er Chen
Synthesis of novel uracil non-nucleoside derivatives as potential reverse transcriptase inhibitors of HIV-1.
November 2009, Archiv der Pharmazie,
Xiao-Dong Ma, and Xuan Zhang, and Hui-Fang Dai, and Shi-Qiong Yang, and Liu-Meng Yang, and Shuang-Xi Gu, and Yong-Tang Zheng, and Qiu-Qin He, and Fen-Er Chen
Discovery of Phenylaminopyridine Derivatives as Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
August 2012, ACS medicinal chemistry letters,
Xiao-Dong Ma, and Xuan Zhang, and Hui-Fang Dai, and Shi-Qiong Yang, and Liu-Meng Yang, and Shuang-Xi Gu, and Yong-Tang Zheng, and Qiu-Qin He, and Fen-Er Chen
Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
September 2009, Bioorganic & medicinal chemistry letters,
Xiao-Dong Ma, and Xuan Zhang, and Hui-Fang Dai, and Shi-Qiong Yang, and Liu-Meng Yang, and Shuang-Xi Gu, and Yong-Tang Zheng, and Qiu-Qin He, and Fen-Er Chen
Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
August 2006, Bioorganic & medicinal chemistry letters,
Xiao-Dong Ma, and Xuan Zhang, and Hui-Fang Dai, and Shi-Qiong Yang, and Liu-Meng Yang, and Shuang-Xi Gu, and Yong-Tang Zheng, and Qiu-Qin He, and Fen-Er Chen
Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
August 2009, Bioorganic & medicinal chemistry,
Xiao-Dong Ma, and Xuan Zhang, and Hui-Fang Dai, and Shi-Qiong Yang, and Liu-Meng Yang, and Shuang-Xi Gu, and Yong-Tang Zheng, and Qiu-Qin He, and Fen-Er Chen
Novel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.
June 2012, ACS medicinal chemistry letters,
Copied contents to your clipboard!